The patient’s declining condition was accompanied by worsening laboratory parameters, including elevated prothrombin time, international normalized ratio (INR), and fibrin degradation products, highlighting the insidious progression of DIC in cancer patients, particularly in the context of adenocarcinoma. This evidence concerns the gene F2 and cancer.